CL2016001570A1 - Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas - Google Patents

Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Info

Publication number
CL2016001570A1
CL2016001570A1 CL2016001570A CL2016001570A CL2016001570A1 CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1 CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1
Authority
CL
Chile
Prior art keywords
activity
vortioxetine
treatment
depressive disorder
receptor antagonist
Prior art date
Application number
CL2016001570A
Other languages
English (en)
Spanish (es)
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2016001570A1 publication Critical patent/CL2016001570A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2016001570A 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas CL2016001570A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16

Publications (1)

Publication Number Publication Date
CL2016001570A1 true CL2016001570A1 (es) 2016-12-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001570A CL2016001570A1 (es) 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Country Status (14)

Country Link
US (1) US10376506B2 (enExample)
EP (1) EP3082815B1 (enExample)
JP (1) JP6448645B2 (enExample)
KR (1) KR20160093025A (enExample)
CN (1) CN105828821B (enExample)
AU (1) AU2014368548B2 (enExample)
CA (1) CA2933733A1 (enExample)
CL (1) CL2016001570A1 (enExample)
ES (1) ES2694352T3 (enExample)
IL (1) IL246253A0 (enExample)
MX (1) MX368870B (enExample)
RU (1) RU2679661C1 (enExample)
SG (1) SG11201604944PA (enExample)
WO (1) WO2015091833A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45532A (fr) * 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US11865112B2 (en) 2018-11-06 2024-01-09 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
TW202547487A (zh) * 2024-03-18 2025-12-16 學校法人東京理科大學 失樂症的治療或預防用醫藥組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
PT1485051E (pt) * 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
PL2001456T3 (pl) * 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
AU2011325563B2 (en) 2010-11-05 2015-08-20 H. Lundbeck A/S Method for the manufacturing of naltrexone
CA2899455C (en) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
JP6416213B2 (ja) * 2013-04-17 2018-10-31 ハー・ルンドベック・アクチエゼルスカベット 気分障害患者の治療のためのナルメフェン

Also Published As

Publication number Publication date
RU2679661C1 (ru) 2019-02-12
AU2014368548A1 (en) 2016-06-30
EP3082815B1 (en) 2018-10-03
MX368870B (es) 2019-10-21
SG11201604944PA (en) 2016-07-28
CN105828821B (zh) 2019-04-09
JP2016540030A (ja) 2016-12-22
EP3082815A1 (en) 2016-10-26
US10376506B2 (en) 2019-08-13
AU2014368548B2 (en) 2019-09-19
CA2933733A1 (en) 2015-06-25
ES2694352T3 (es) 2018-12-20
IL246253A0 (en) 2016-07-31
RU2016123972A (ru) 2018-01-25
CN105828821A (zh) 2016-08-03
KR20160093025A (ko) 2016-08-05
US20160310488A1 (en) 2016-10-27
JP6448645B2 (ja) 2019-01-09
MX2016007947A (es) 2016-09-09
WO2015091833A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
MX368870B (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
SI2956471T1 (sl) Sestava za zaviralca il-1beta in njegova uporaba
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral
IL245811B (en) Pharmaceutical preparations with hydration and lubrication activity
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
UY34829A (es) Nueva dosificación y formulación
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.